Proposal for a standard report format for economic evaluations;Voorstel voor gestandaardiseerde rapportage van economische evaluaties

Pharmaceutisch Weekblad

Volumn 132, Issue 9, 1997, Pages 268-271

  Pronk, M H ^a   Brorens, M J A ^b   Eschauzier, A M ^b   Hardens, M ^b   Hekster, Y A ^b   Van Der Kuy, A ^b   Lockefeer, J H M ^b   De Smet, P A G M ^b  

^a Pronk Healthcare Consultancy BV   (Netherlands)

^b NONE

Author keywords

economics, pharmaceutical; guidelines; health care costs; publishing; research

Indexed keywords

ECONOMICS; EVALUATION AND FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; SHORT SURVEY;

EID: 0030816180     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. Commissie Keuzen in de zorg. Kiezen en delen. Rijswijk: Ministerie van Volksgezondheid, Welzijn en Sport, 1991.
2. Torrance GW, Blaker D, Detsky A, Kennedy W, Schubert F, Menon D, et al. Canadian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1996;9(6):535-59.
3. Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus P, Bobula J. Methodological and conduct principles for pharmacoeconomics research. Pharmacoeconomics 1995;8(2):169-74.
4. Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical benefits advisory committee. Canberra: Commonwealth Department of Human Services and Health, 1995.
5. A proposal for methodological guidelines for economic evaluation of pharmaceuticals. Gent: Belgian Society for Pharmacoepidemiology, 1995.
6. Garattini L, Grilli R, Scoopelliti F, Mantovani L. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics 1995;7(1):1-6.
7. Van der Schulenburg JM (Graf), Greiner W. "Hannover Guidelines" für die ökonomische Evaluation von Gesundheitsgütern und -dienstleistungen. Pharm Ind 1995;57(4):265-8.
8. Brecht JG, Jenke A, Köhler ME, Harder S, Thürmann P, Riebrook N. Empfehlungen der Deutsche Gesellschaft für klinische Pharmakologie und Therapie zur Durchführung und Bewertung pharmakoökonomische Studien. Klin Pharmakol Akt 1995;6(1):4-11.
9. Acceptabilité des etudes medico-economiques - Contenu et presentation. Parijs: Commission de Transparence, 1995.
10. Gelber RD, Cole BF, Belber S, Goldhirsch A. The Q-TWIST method. In: Spilker B, red. Quality of life and pharmacoeconomics in clinical trials. 2e ed. Philadelphia/New York: Lippincott/Raven Publishers, 1996.
11. Torrance GW, Feeny D. Utilities and quality adjusted life years. Int J Technol Assess Health Care 1989;5:559-75.
12. Hardens M, Leufkens HGM. Farmaco-economie in Nederland. Pharm Weekbl 1996;(speciale uitgave):71-5.
13. Breimer DD, Broekmans AW, Leufkens HGM, Rutten FFH, red. Pharmaco-economics. Leiden: Boerhaave commissie voor postacademisch onderwijs in de geneeskunde, 1995.
14. Jefferson T, Demichelli V. Are guidelines for peer-reviewing economic evaluation necessary? A survey of current editorial practice. Health Econ 1995;4:383-8.
15. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
16. Van Luijn JCF, Van Loenhout JWA, Riteco JA, Ripken T. Toetsing van het geneesmiddelenpakket. Het beslismodel extramurale farmaceutische hulp van de Ziekenfondsraad. Pharm Weekbl 1995;129(51/52):1392-7.